PurGenesis Technologies, Inc.
🇨🇦Canada
Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis Eczema
- Interventions
- Drug: Administration of PlaceboDrug: Administration of PUR0110 (Thykamine) 0.05%Drug: Administration of PUR0110 (Thykamine) 0.1%Drug: Administration of PUR0110 (Thykamine) 0.25%
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT03540043
- Locations
- 🇨🇦
Dr. David Gratton Dermatologue Inc., Montréal, Quebec, Canada
🇨🇦Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ), Québec, Canada
🇨🇦Windsor Clinical Research Inc., Windsor, Ontario, Canada
A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers
Phase 1
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PUR 0110 Rectal Enema or Placebo Enema
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2010-06-24
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01149694
- Locations
- 🇩🇪
FOCUS Clinical Drug Development GmbH Phase 1 Clinic, Neuss, Germany
Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis
Phase 2
Completed
- Conditions
- ProctosigmoiditisLeft-Sided Ulcerative Colitis
- Interventions
- Drug: PUR 0110 Rectal Enema 250 mgDrug: PUR 0110 Rectal Enema 500 mgDrug: Placebo EnemaDrug: PUR 0110 Rectal Enema 1000 mg
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- PurGenesis Technologies Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01149707
- Locations
- 🇩🇪
PurGenesis Investigational Site, Werden, Germany
© Copyright 2025. All Rights Reserved by MedPath